We observed that the suppression of CDKN2B-AS1 resulted in the upregulation of CDKN2B in TMs and HEK292T cells, which are in accordance with previous reports in vascular smooth muscle cells [49] and cancer cell lines [50]. This evidence concerns the gene CDKN2B and cancer.